AK117/Placebo with Azacitidine
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 90 patients (estimated)
- Sponsors
- Akeso
- Tags
- Monoclonal Antibody, CD47, Closed Label (Masked), Placebo, Randomization
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1855
- NCT Identifier
- NCT06196203
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.